surmount-1 tirzepatide weight loss percent 72 weeks SURMOUNT-1: Drastically Reduces in Obese Patients Semaglutide vs. Tirzepatide for Obesity

Lymphir, Citius first FDA-approved product, is a reformulation of the FDA-approved cancer treatment denileukin diftitox, which combines the IL-2 cytokine and the diphtheria toxin

Accordingly, in the overall SURMOUNT-1 study, the mean decrease in waist circumference was 18.5 cm with tirzepatide 15 mg [55]

Others undergo cosmetic procedures after weight loss to address loose skin or body contours

Tirzepatide can tolerate brief periods at room temperature, but extended exposure above 8 degrees Celsius accelerates degradation

For several SOCs with the highest number of adverse reactions, the median TTOs were all less than one week such as administration site conditions (4.91 [0.6324.88] days) and gastrointestinal disorders (5.57 [0.7527.09] days)

Be prepared to adjust your goals and expectations based on your progress